Amino acid may reduce damage caused by Alzheimer’s, study suggests

A study published in the journal Neurochemistry International suggests that arginine, a common and low-cost amino acid, may offer a new approach to combating Alzheimer’s disease. Researchers at Kindai University found that arginine may reduce the accumulation of toxic amyloid proteins in the brain, a hallmark of the disease.

Evidence on the role of arginine

The research found that arginine acts as a safe chemical chaperone, helping proteins maintain their proper structure. Scientists observed that arginine can inhibit the formation of Aβ42 aggregates, which are particularly toxic. The study also showed that administering arginine in animal models led to a reduction in the accumulation of these harmful proteins.

Results in animal models

In Alzheimer’s models, including fruit flies and genetically modified mice, arginine not only reduced Aβ accumulation but also improved the animals’ behavioral performance. The researchers highlighted that arginine demonstrated effectiveness both in vitro and in vivo, showing promising results for potential disease treatment.

Impact on brain health and inflammation

The benefits of arginine go beyond reducing protein buildup. In mouse models, it also lowered levels of amyloid plaques and reduced the activity of genes associated with pro-inflammatory cytokines, which are linked to neuroinflammation—a key aspect of Alzheimer’s disease. This suggests that arginine may provide broader protection for brain cells.

Prospects for low-cost treatments

The study highlights the potential of drug repositioning, which explores new applications for already existing compounds. Arginine, already used clinically in Japan and with an established safety profile, may facilitate the transition into clinical trials. However, the researchers caution that further preclinical and clinical studies are still needed to validate these findings in humans and determine the best dosing strategies.

The findings on arginine open new possibilities for developing therapeutic strategies targeting neurodegenerative diseases, offering a promising and low-cost alternative for Alzheimer’s treatment.